Share Your Story

Share
NEWS ABOUT DARZALEX®

PATIENT SITE

Discover

More Possibilities

A new option for patients with multiple myeloma: DARZALEX® can now be used in combination with Revlimid® (lenalidomide) and dexamethasone or Velcade® (bortezomib) and dexamethasone in patients who have received at least one prior medicine.

How does DARZALEX® work?
  • DARZALEX® is not chemotherapy. DARZALEX® is a monoclonal antibody that works with your immune system. Monoclonal antibodies work by attaching themselves to multiple myeloma cells in your body and directly killing them, and/or signaling your immune system to destroy them
  • DARZALEX® finds and attaches to a protein called CD38, which is present on the surface of cells, including high numbers on myeloma cells
RESULTS SEEN IN CLINICAL TRIALS
  • The main goal of the study was to measure the length of time patients live without their multiple myeloma getting worse or their passing away from any cause
    • Another goal was to measure response rate, which is the percentage of patients who responded to treatment. Talk to your doctor about how response is measured
  • The majority of patients responded to the following DARZALEX® combination treatments:
    • ​DARZALEX® was studied in combination with Revlimid® and dexamethasone (Rd) vs Rd alone in 569 patients who had received a minimum of 1 prior treatment
      • 9 out of 10 patients responded to DARZALEX® + Rd vs 7 out of 10 with Rd alone
    • DARZALEX® was studied in combination with Velcade® and dexamethasone (Vd) vs Vd alone in 498 patients who had received a minimum of 1 prior treatment
      • Almost 8 out of 10 patients responded to DARZALEX® + Vd vs almost 6 out of 10 with Vd alone
  • DARZALEX® combination treatments reduced patients’ risk of their disease getting worse or their passing away from any cause by more than 60%

Sign up to receive updates and more information.

Click here if you are a healthcare professional.

Revlimid® is a registered trademark of Celgene Corporation.
Velcade® is a registered trademark of Millennium Pharmaceuticals, Inc.

Inspire Others by Telling Your Story Through the SHARE Network 

Janssen Biotech, Inc., the maker of DARZALEX® (daratumumab), invites you to help inspire others by telling your story through the SHARE Network. To get started, provide your information below. A representative will reach out to finish your registration process and schedule a short phone call at a time that works for you. Interviews usually take less than 30 minutes. Every question we ask is optional, and we only want to hear what you’re comfortable sharing.

Thank you for your interest in participating.

*Required field

*Please select a preferred 30-minute window between 8:00 am and 8:00 pm ET for us to call


08:30 am

By providing your information, you are asking us to tell you more about the SHARE Network. The SHARE Network, a Janssen Global Services, LLC, program, will receive your information, and it will be shared with its affiliates and third parties involved in the SHARE Network in fulfillment of this and any optional requests. If at any time you decide to withdraw from SHARE Network communications, please call toll-free 1-855-369-1305 or e-mail info@sharemyjanssenstory.com. The information you provide may also be used by Janssen Biotech, Inc., the marketer of DARZALEX® (daratumumab), and companies working on their behalf, including vendors and other affiliates, to fulfill your request and provide you with additional information and services from Janssen Biotech, Inc. If you want to stop receiving this information or service, you may call 1-877-227-3728. All information you provide here will be governed by the Janssen Biotech, Inc., Privacy Policy, which can be found at darzalex.com/privacy-policy, and the SHARE Network Privacy Policy, which can be found at sharemyjanssenstory.com/privacy/. By providing your information and clicking the SUBMIT button, you are confirming that you have read, understand, and agree to these conditions.